Cardiff Oncology (CRDF) vs enGene Therapeutics (ENGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Cardiff Oncology (CRDF) has outperformed enGene Therapeutics (ENGN) over the past year, losing 54.6% versus a loss of 80.5%. enGene Therapeutics is the larger company by market cap ($115.9 million vs $84.0 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDF | ENGN |
|---|---|---|
| Share price | $1.08 | $1.73 |
| Market cap | $84.02M | $115.94M |
| 1-day change | +1.89% | -2.81% |
| YTD return | -61.57% | -80.84% |
| 1-year return | -54.62% | -80.54% |
| 5-year return | -83.13% | — |
| EPS (TTM) | $-0.60 | $-2.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.31 | $12.25 |
| 52-week low | $0.76 | $1.40 |
| Distance from 52-week high | -67.37% | -85.88% |
| Analyst consensus | none | none |
| Avg. price target upside | +437.96% | +90.17% |
| Average volume | 1.04M | 736.63K |
| Shares outstanding | 77.80M | 67.02M |
| Employees | 30 | 81 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDF has outperformed ENGN by 25.9 percentage points over the past year.
About Cardiff Oncology
CRDF stock →Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 30 employees
About enGene Therapeutics
ENGN stock →enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
CRDF vs ENGN FAQ
Which is bigger, Cardiff Oncology or enGene Therapeutics?
enGene Therapeutics (ENGN) is larger, with a market capitalization of $115.94M compared with $84.02M for Cardiff Oncology (CRDF).
Which stock has performed better over the past year, CRDF or ENGN?
CRDF returned -54.62% over the past 12 months, compared with -80.54% for ENGN (price return, excluding dividends). Past performance does not predict future results.
Are Cardiff Oncology and enGene Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.